![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
Citations (44)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (11)
Benchalak Maneeton, Narong Maneeton, Surinporn Likhitsathian, Pakapan Woottiluk, Punjaree Wiriyacosol, Vudhichai Boonyanaruthee & Manit Srisurapanont. (2018) Escitalopram vs duloxetine in acute treatment of major depressive disorder: meta-analysis and systematic review. Neuropsychiatric Disease and Treatment 14, pages 1953-1961.
Read now
Read now
Sean Wharton, Lilian Raiber, Kristin J Serodio, Jasmine Lee & Rebecca AG Christensen. (2018) Medications that cause weight gain and alternatives in Canada: a narrative review. Diabetes, Metabolic Syndrome and Obesity 11, pages 427-438.
Read now
Read now
Eiji Harada, Alexander Schacht, Tsukasa Koyama, Lauren B Marangell, Toshinaga Tsuji & Rodrigo Escobar. (2015) Efficacy comparison of duloxetine and SSRIs at doses approved in Japan. Neuropsychiatric Disease and Treatment 11, pages 115-123.
Read now
Read now
Pierre-Michel Llorca, Christophe Lançon, Mélanie Brignone, Benoît Rive, Samir Salah, Larry Ereshefsky & Clément Francois. (2014) Relative efficacy and tolerability of vortioxetine versus selected antidepressants by indirect comparisons of similar clinical studies. Current Medical Research and Opinion 30:12, pages 2589-2606.
Read now
Read now
Lanny Bochsler, James S Olver & Trevor R Norman. (2011) Duloxetine in the acute and continuation treatment of major depressive disorder. Expert Review of Neurotherapeutics 11:11, pages 1525-1539.
Read now
Read now
Junling Wang, Xianchen Liu & C. Daniel Mullins. (2011) Treatment adherence and persistence with duloxetine, venlafaxine XR, and escitalopram among patients with major depressive disorder and chronic pain-related diseases. Current Medical Research and Opinion 27:7, pages 1303-1313.
Read now
Read now
Rodrigo CL Edelmuth, Michael A Nitsche, Linamara Battistella & Felipe Fregni. (2010) Why do some promising brain-stimulation devices fail the next steps of clinical development?. Expert Review of Medical Devices 7:1, pages 67-97.
Read now
Read now
Chi-Un Pae, Patrick Luyten, David M. Marks, Changsu Han, Sung-Hwan Park, Ashwin A. Patkar, Prakash S. Masand & Boudewijn Van Houdenhove. (2008) The relationship between fibromyalgia and major depressive disorder: a comprehensive review. Current Medical Research and Opinion 24:8, pages 2359-2371.
Read now
Read now
Cyril Höschl & Jaromír Švestka. (2008) Escitalopram for the treatment of major depression and anxiety disorders. Expert Review of Neurotherapeutics 8:4, pages 537-552.
Read now
Read now
Norbert Müller, Rebecca Schennach, Michael Riedel & Hans-Jürgen Möller. (2008) Duloxetine in the treatment of major psychiatric and neuropathic disorders. Expert Review of Neurotherapeutics 8:4, pages 527-536.
Read now
Read now
Carlos Blanco, Mayumi Okuda, Hannah Rosenthal & Roberto Lewis-Fernandez. (2008) Duloxetine in the treatment of major depression and other psychiatric disorders. Expert Review of Clinical Pharmacology 1:2, pages 195-205.
Read now
Read now
Articles from other publishers (33)
Hartej Gill, Barjot Gill, Sabine El‐Halabi, David Chen‐Li, Orly Lipsitz, Joshua Daniel Rosenblat, Tamsyn E. Van Rheenen, Nelson B. Rodrigues, Rodrigo B. Mansur, Amna Majeed, Leanna M. W. Lui, Flora Nasri, Yena Lee & Roger S. Mcintyre. (2020) Antidepressant Medications and Weight Change: A Narrative Review. Obesity 28:11, pages 2064-2072.
Crossref
Crossref
Daniela Rodrigues-Amorim, José Manuel Olivares, Carlos Spuch & Tania Rivera-Baltanás. (2020) A Systematic Review of Efficacy, Safety, and Tolerability of Duloxetine. Frontiers in Psychiatry 11.
Crossref
Crossref
Guanjun Li, Yifeng Shen, Jianfeng Luo & Huafang Li. (2017) Efficacy of escitalopram monotherapy in the treatment of major depressive disorder. Medicine 96:39, pages e8142.
Crossref
Crossref
Andy Wolff, Revan Kumar Joshi, Jörgen Ekström, Doron Aframian, Anne Marie Lynge Pedersen, Gordon Proctor, Nagamani Narayana, Alessandro Villa, Ying Wai Sia, Ardita Aliko, Richard McGowan, Alexander Ross Kerr, Siri Beier Jensen, Arjan Vissink & Colin Dawes. (2016) A Guide to Medications Inducing Salivary Gland Dysfunction, Xerostomia, and Subjective Sialorrhea: A Systematic Review Sponsored by the World Workshop on Oral Medicine VI. Drugs in R&D 17:1, pages 1-28.
Crossref
Crossref
W. Bentley MacLeod. (2017) Viewpoint: The human capital approach to inference. Canadian Journal of Economics/Revue canadienne d'économique 50:1, pages 5-39.
Crossref
Crossref
Arash Mowla, Sanaz Boostani & Seyed Ali Dastgheib. (2016) Duloxetine Augmentation in Resistant Obsessive-Compulsive Disorder. Journal of Clinical Psychopharmacology 36:6, pages 720-723.
Crossref
Crossref
Arash Mowla, Seyed Ali Dastgheib & Leila Razeghian Jahromi. (2016) Comparing the Effects of Sertraline with Duloxetine for Depression Severity and Symptoms: A Double-Blind, Randomized Controlled Trial. Clinical Drug Investigation 36:7, pages 539-543.
Crossref
Crossref
Leslie Citrome. (2016) Vortioxetine for major depressive disorder: An indirect comparison with duloxetine, escitalopram, levomilnacipran, sertraline, venlafaxine, and vilazodone, using number needed to treat, number needed to harm, and likelihood to be helped or harmed. Journal of Affective Disorders 196, pages 225-233.
Crossref
Crossref
E. Harada, M. Kato, S. Fujikoshi, M. M. Wohlreich, L. Berggren & H. Tokuoka. (2015) Changes in energy during treatment of depression: an analysis of duloxetine in double‐blind placebo‐controlled trials. International Journal of Clinical Practice 69:10, pages 1139-1148.
Crossref
Crossref
Roland W. Freudenmann, Ninja Freudenmann, Bartosz Zurowski, Carlos Schönfeldt-Lecuona, Bernhard J. Connemann, Maximilian Gahr & Roland Freudenmann. (2015) Better Risk Assessment for Individual Substances. Deutsches Ärzteblatt international.
Crossref
Crossref
Michael Robinson, Tina Myers Oakes, Joel Raskin, Peng Liu, Scarlett Shoemaker & J. Craig Nelson. (2014) Acute and Long-term Treatment of Late-Life Major Depressive Disorder: Duloxetine Versus Placebo. The American Journal of Geriatric Psychiatry 22:1, pages 34-45.
Crossref
Crossref
Caroline T. Nguyen, Michael I. MacEntee, Barbara Mintzes & Thomas L. Perry. (2013) Information for Physicians and Pharmacists About Drugs That Might Cause Dry Mouth: A Study of Monographs and Published Literature. Drugs & Aging 31:1, pages 55-65.
Crossref
Crossref
Julie C. Locklear, Henrik Sveds?ter, Catherine Datto & Jean Endicott. (2013) Effects of once-daily extended release quetiapine fumarate (quetiapine XR) on quality of life and sleep in elderly patients with major depressive disorder. Journal of Affective Disorders 149:1-3, pages 189-195.
Crossref
Crossref
Andrew Lai Huat Peh, Chan Herng Nieng, Yap Hwa Ling, Tay Woo Kheng, Tan Sheng Neng & Ong Guan Koon. (2013) The effect of escitalopram on metabolic parameters in patients with major depressive disorder, generalised anxiety disorder, and panic disorder: A prospective 6-month follow-up study. Asian Journal of Psychiatry 6:3, pages 256-257.
Crossref
Crossref
Jill C. Chappell, Richard Kovacs, Harry Haber, Ryan Wright, Malcolm I. Mitchell, Michael Detke & Beth Pangallo. (2013) Evaluation of the Effects of Duloxetine and Escitalopram on 24-Hour Heart Rate Variability. Journal of Clinical Psychopharmacology 33:2, pages 236-239.
Crossref
Crossref
Andrea Cipriani, Markus Koesters, Toshi A Furukawa, Michela Nosè, Marianna Purgato, Ichiro M Omori, Carlotta Trespidi & Corrado Barbui. (2012) Duloxetine versus other anti-depressive agents for depression. Cochrane Database of Systematic Reviews.
Crossref
Crossref
Anjana Bose, Joyce Tsai & Dayong Li. (2012) Early Non-Response in Patients with Severe Depression. Clinical Drug Investigation 32:6, pages 373-385.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Obesity and Psychotropics. CNS Neuroscience & Therapeutics 18:1, pages 57-63.
Crossref
Crossref
J. Craig Nelson. (2011) Effects of Baseline Depression Severity on Remission Rates With Duloxetine and Placebo in Anxious and Nonanxious Patients With Major Depression. Journal of Clinical Psychopharmacology 31:5, pages 682-684.
Crossref
Crossref
Nikhil Nihalani, Thomas L. Schwartz, Umar A. Siddiqui & James L. Megna. (2011) Weight Gain, Obesity, and Psychotropic Prescribing. Journal of Obesity 2011, pages 1-9.
Crossref
Crossref
Andrea Pierò & Enrica Locati. (2011) An open, non‐randomised comparison of escitalopram and duloxetine for the treatment of subjects with Generalized Anxiety Disorder. Human Psychopharmacology: Clinical and Experimental 26:1, pages 63-71.
Crossref
Crossref
Karly P. Garnock-Jones & Paul L. McCormack. (2010) Escitalopram. CNS Drugs 24:9, pages 769-796.
Crossref
Crossref
Brian Leonard & David Taylor. (2010) Review: Escitalopram—translating molecular properties into clinical benefit: reviewing the evidence in major depression. Journal of Psychopharmacology 24:8, pages 1143-1152.
Crossref
Crossref
J. Craig Nelson. (2010) Anxiety does not predict response to duloxetine in major depression: results of a pooled analysis of individual patient data from 11 placebo-controlled trials. Depression and Anxiety 27:1, pages 12-18.
Crossref
Crossref
Gerald Gartlehner, Kylie Thaler, Richard A. Hansen & Bradley N. Gaynes. (2009) The General and Comparative Efficacy and Safety of Duloxetine in Major Depressive Disorder. Drug Safety 32:12, pages 1159-1173.
Crossref
Crossref
Puwen Zhang, Eugene A. Terefenko, Jenifer Bray, Darlene Deecher, Andrew Fensome, Jim Harrison, Callain Kim, Elizabeth Koury, Lilly Mark, Casey C. McComas, Cheryl A. Mugford, Eugene J. Trybulski, An T. Vu, Garth T. Whiteside & Paige E. Mahaney. (2009)
1- or 3-(3-Amino-2-hydroxy-1-phenyl propyl)-1,3-dihydro-2
H
-benzimidazol-2-ones: Potent, Selective, and Orally Efficacious Norepinephrine Reuptake Inhibitors
. Journal of Medicinal Chemistry 52:18, pages 5703-5711.
Crossref
Crossref
Susan G. Kornstein, Dayong Li, Yongcai Mao, Sara Larsson, Henning F. Andersen & George I. Papakostas. (2014)
Escitalopram Versus SNRI Antidepressants in the Acute Treatment of Major Depressive Disorder:
Integrative Analysis of Four Double-Blind, Randomized Clinical Trials
. CNS Spectrums 14:6, pages 326-333.
Crossref
Crossref
Sylvia ZerjavGordon TseMichael J.W. Scott. (2009) Review of Duloxetine and Venlafaxine in Depression. Canadian Pharmacists Journal / Revue des Pharmaciens du Canada 142:3, pages 144-152.e6.
Crossref
Crossref
Katsumasa Muneoka. (2009) Pharmacotherapy of Major Depressive Disorder: Focus on Duloxetine. Clinical Medicine. Therapeutics 1, pages CMT.S1988.
Crossref
Crossref
Ripu D. Jindal. (2009) Insomnia in Patients with Depression. CNS Drugs 23:4, pages 309-329.
Crossref
Crossref
Lawrence D. Ginsberg. (2014) Impact of Drug Tolerability on the Selection of Antidepressant Treatment in Patients With Major Depressive Disorder. CNS Spectrums 14:S12, pages 8-14.
Crossref
Crossref
A. Prakash, R. C. Risser & C. H. Mallinckrodt. (2008) The impact of analytic method on interpretation of outcomes in longitudinal clinical trials. International Journal of Clinical Practice 62:8, pages 1147-1158.
Crossref
Crossref
Anita Clayton, Susan Kornstein, Apurva Prakash, Craig Mallinckrodt & Madelaine Wohlreich. (2007) ORIGINAL RESEARCH—PSYCHOLOGY: Changes in Sexual Functioning Associated with Duloxetine, Escitalopram, and Placebo in the Treatment of Patients with Major Depressive Disorder. The Journal of Sexual Medicine 4:4, pages 917-929.
Crossref
Crossref